Literature DB >> 33583133

Managing mucormycosis in diabetic patients: A case report with critical review of the literature.

Fabian M Beiglboeck1,2,3, Nantia E Theofilou1, Matthias D Fuchs1, Matthias G Wiesli1, Christoph Leiggener1, Sebastian Igelbrink3, Marcello Augello1.   

Abstract

BACKGROUND AND
PURPOSE: Rhino-orbito-cerebral mucormycosis (ROCM) is a rare and potentially fatal invasive fungal infection which usually occurs in diabetic and other immunocompromised patients. This infection is associated with high morbidity and mortality rates. Prompt diagnosis and rapid aggressive surgical debridement and antimycotic therapy are essential for the patient's survival. Herein, we reviewed the localization and treatment strategies in patients with ROCM and diabetes as an underlying condition. Furthermore, we report one case of ROCM in our department.
MATERIALS AND METHODS: From 117 identified studies published in PubMed, 14 publications-containing data from 54 patients-were included. All patients were diagnosed clinically and by histopathological and/or bacteriological analysis for ROCM caused by the order Mucorales.
CONCLUSION: Uncontrolled diabetes mellitus is one of the main risk factors for ROCM. A successful management of ROCM requires an early diagnosis, a prompt systemic antifungal therapy, and a rapid aggressive surgical debridement including exploration of the pterygopalatine fossa. An orbital exenteration may be necessary.
© 2021 The Authors. Oral Diseases published by Wiley Periodicals LLC.

Entities:  

Keywords:  dental; diabetes; exenteration; mucormycosis; rhino-orbito-cerebral; rhizopus oryzae

Mesh:

Substances:

Year:  2021        PMID: 33583133     DOI: 10.1111/odi.13802

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  3 in total

1.  Isolated splenic mucormycosis secondary to diabetic ketoacidosis: a case report.

Authors:  Shuai Luo; Xiang Huang; Yao Li; Jinjing Wang
Journal:  BMC Infect Dis       Date:  2022-07-07       Impact factor: 3.667

2.  A Vaccine Construction against COVID-19-Associated Mucormycosis Contrived with Immunoinformatics-Based Scavenging of Potential Mucoralean Epitopes.

Authors:  Muhammad Naveed; Urooj Ali; Mohmed Isaqali Karobari; Naveed Ahmed; Roshan Noor Mohamed; Shahabe Saquib Abullais; Mohammed Abdul Kader; Anand Marya; Pietro Messina; Giuseppe Alessandro Scardina
Journal:  Vaccines (Basel)       Date:  2022-04-22

3.  Successful treatment of rhino-cerebral mucormycosis with dual antifungal therapy and minimal surgical debridement.

Authors:  Lauren Bougioukas; Cindy D Noyes; Katherine Peterson; Lindsay M Smith; Andrew J Hale
Journal:  IDCases       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.